4D Molecular TherapeuticsvsMerck & Company

FDMT and MRK stock compared: price, dividend, valuation and results, from SEC filings.

FDMT

4D Molecular Therapeutics, Inc.

$12.23

Value $884M

+0.95%
FDMT's page

MRK

Merck & Company, Inc.

$147.76

Value $365B

+0.55%
MRK's page

4D Molecular Therapeutics (FDMT) has a market value of $884M and Merck & Company (MRK) $365B. Over the last year, with dividends, FDMT moved +11.5% and MRK +66.3%. Dividend yield: FDMT none, MRK 2.30%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    FDMT$884M

    MRK$365B

    MRK is 413 times FDMT

  • Revenue, 12 months

    FDMT$96M

    MRK$67.4B

    MRK is 701 times FDMT

  • Net income, 12 months

    FDMT-$200M

    MRK$2.5B

  • Operating margin

    FDMT-226.0%

    MRK–

  • ROIC

    FDMT-41.4%

    MRK3.9%

    45.3 points apart

  • P/E

    FDMT–

    MRK148.9

  • Dividend yield

    FDMT0.0%

    MRK2.3%

    2.3 points apart

  • 5-year return

    FDMT-51.0%

    MRK+104.9%

    155.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

FDMT-51.0%

MRK+104.9%

010020020222023202420252026
Returns by period
PeriodFDMTWith dividendsMRKWith dividends
1 year since November 12, 2025+11.5%Price +11.5%+66.3%Price +61.6%
3 years since November 13, 2023+16.1%+5.1% a yearPrice +16.1%+58.0%+16.5% a yearPrice +44.2%
5 years since November 12, 2021-51.0%-13.3% a yearPrice -51.0%+104.9%+15.4% a yearPrice +75.9%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

FDMT4D Molecular TherapeuticsMRKMerck & Company

Valuation

FDMTMRK
Valuation
Price$12.23$147.76
Market value$884M$365B
Enterprise value (EV)$596M$409B
P/E–148.9
P/E, 5-year median–14.8
P/B2.68.1
EV/EBIT–86.0
Free cash flow yield–4.0%

Results and growth

FDMTMRK
Results and growth
Revenue, 12 months$96M$67.4B
Net income, 12 months-$200M$2.5B
Free cash flow, 12 months-$166M$14.7B
Earnings per share, 12 months-$2.70$0.98
Revenue growth, year on year230,194.6%1.3%
Revenue growth a year, past+44.9%over 5 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

FDMTMRK
Margins and returns on capital
Gross margin–71.8%
Operating margin-226.0%–
Net margin-208.6%3.6%
ROIC-41.4%3.9%
ROE-48.4%5.2%

Balance sheet

FDMTMRK
Balance sheet
Cash$307M$9.7B
Total debt$38M$53.8B
Net debt / EBITDA–5.7
Interest cover–2.4×

Dividends and buybacks

FDMTMRK
Dividends and buybacks
Dividend yield–2.3%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.4%
Shareholder yield–3.7%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: FDMT or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, 4D Molecular Therapeutics or Merck & Company?

By market value, Merck & Company ($365B) is about 413.4 times 4D Molecular Therapeutics ($884M), at today's prices.

How did FDMT and MRK stock do over the last 5 years?

Since November 12, 2021, FDMT's price moved -51.0% and MRK's +75.9%. With dividends: FDMT -51.0% (-13.3% a year), MRK +104.9% (+15.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, FDMT or MRK?

The dividend yield at today's price is none for 4D Molecular Therapeutics and 2.30% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, 4D Molecular Therapeutics or Merck & Company?

Over the last twelve months, the net margin was -208.6% for 4D Molecular Therapeutics and 3.6% for Merck & Company, and the operating margin -226.0% and –. Revenue was $96M and $67.4B.

Which is the better investment, 4D Molecular Therapeutics or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.